Mundipharma announces Marco Cerato as Senior Vice President Business Development and Strategic Partnerships

flutiform® receives a positive opinion in Europe for the Treatment of Children with Asthma

New guidance from ADA and EASD recommends use of sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for patients with type 2 diabetes

Mundipharma strengthens position as a leader in biosimilars with acquisition of development company Cinfa Biotech

Mundipharma announces Philippe Bastide as Head of Biosimilars

flutiform® k-haler®, a Novel Treatment for Adolescents and Adults with Asthma, now Available in Europe

Innovative pharmaceutical pricing agreements preferable to discounts, according to new European payer survey

The CHMP issues positive opinion to expand INVOKANA® and VOKANAMET® labels to include positive data on cardiovascular and renal outcomes

Mundipharma International welcomes positive phase III efficacy findings for Invokana® (canagliflozin) in type 2 diabetes patients with chronic kidney disease

Herzuma® (trastuzumab), a biosimilar for the treatment of breast cancer, now available in Europe